International Journal of Infectious Diseases · 2023 · 14 citations · 11 references
PharmacyInfectious DiseasesPharmacotherapyClinical EpidemiologyCritical Care PharmacotherapyPharmacovigilanceAntiviral TherapyPharmacoepidemiologyTreatment DurationAntiviral Safety AssessmentCohort Study InvestigationControl Group DesignHospitalization BurdenHospitalization ReductionManagement Of High-risk PatientsMatched Control GroupPropensity Score Adjustment
OBJECTIVE: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death. METHODS: This 1:1 propensity score matched cohort study from 647 public health clinics in Malaysia included all patients with COVID-19 with positive tests aged 18 years and older, who were eligible for nirmatrelvir-ritonavir treatment within 5 days of illness from July 14, 2022, to November 14, 2022. The exposed group was patients with COVID-19 initiated with nirmatrelvir-ritonavir treatment, whereas those not initiated with the drug served as the control group. Data was analyzed from July 14, 2022 to December 31, 2022. RESULTS: A total of 20,966 COVID-19 high-risk outpatients (n = 10,483 for nirmatrelvir-ritonavir group and n = 10,483 for control group) were included in the study. Nirmatrelvir-ritonavir treatment was associated with a 36% reduction (adjusted hazard ratio 0.64 [95% CI 0.43, 0.94]) in hospitalization compared with those not given the drug. There was a single ICU admission for the control group and one death each was reported in the nirmatrelvir-ritonavir and control group, respectively. CONCLUSIONS: Nirmatrelvir-ritonavir treatment was associated with reduced hospitalization in high-risk patients with COVID-19 even in highly vaccinated populations.
11
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen et al. · New England Journal of Medicine · 2022 · 367 citations · Full text
Fiona P. Havers, Huong Pham, Christopher A. Taylor et al. · JAMA Internal Medicine · 2022 · 191 citations · Full text
Public Health, Infectious Diseases, Public Health Practice +13